1. Jenkins AJ, Best JD, Klein RL, Lyons TJ: Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metab Res Rev 2004, 20:349-368.
2. Crawford TN, Alfaro DV, Kerrison JB, Jablon EP: Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 2009, 5(1):8-13.
3. Ma JX, Zhang SX, Wang JJ: Down-regulation of angiogenic inhibitors: a potential pathogenic mechanism for diabetic complications. Curr Diabetes Rev 2005, 1(2):183-196.
4. Chen S, Ziyadeh FN: Vascular endothelial growth factor and diabetic nephropathy. Curr Diab Rep 2008, 8(6):470-476.
5. Moulton KS: Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Curr Opin Lipidol 2006, 17(5):548-555.
6. Chen CH, Walterscheid JP: Plaque angiogenesis versus compensatory arteriogenesis in atherosclerosis. Circ Res 2006, 99(8):787-789.
7. Chao J, Miao RQ, Chen V, Chen LM, Chao L: Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol Chem 2001, 382(1):15-21.
8. Miao RQ, Agata J, Chao L, Chao J: Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002, 100(9):3245-3252.
9. Chao J, Yin H, Yao YY, Shen B, Smith RS Jr, Chao L: Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther 2006, 17(12):1201-1213.
10. Chao J, Stallone JN, Liang YM, Chen LM, Wang DZ, Chao L: Kallistatin is a potent new vasodilator. J Clin Invest 1997, 100(1):11-17.
11. Gao L, Yin H, S Smith R Jr, Chao L, Chao J: Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest 2008, 88(11):1157-1166.
12. Shen B, Hagiwara M, Yao YY, Chao L, Chao J: Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension 2008, 51(5):1358-1365.
13. Miao RQ, Murakami H, Song Q, Chao L, Chao J: Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. Circ Res 2000, 86(4):418-424.
14. Chao J, Schmaier A, Chen LM, Yang Z, Chao L: Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med 1996, 127(6):612-620.
15. Wolf WC, Harley RA, Sluce D, Chao L, Chao J: Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem 1999, 47(2):221-228.
16. Hatcher HC, Ma JX, Chao J, Chao L, Ottlecz A: Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 1997, 38(3):658-664.
17. Ma JX, King LP, Yang Z, Crouch RK, Chao L, Chao J: Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. Curr Eye Res 1996, 15(11):1117-1123.
18. Hernández C, Simó R: Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. Expert Opin Investig Drugs 2007, 16(8):1209-1226.
19. Wilson AM, O’Neal D, Nelson CL, Prior DL, Best JD, Jenkins AJ: Comparison of arterial assessments in low and high vascular disease risk groups. Am J Hypertens 2004, 17:285-291.
20. Nelson CL, Karschimkus CS, Dragicevic G, Packham DK, Wilson AM, O’Neal D, Becker GJ, Best JD, Jenkins AJ: Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. Nephrol Dial Transplant 2005, 20:2420-2426.
21. Lee AB, Godfrey T, Rowley KG, Karschimkus CS, Dragicevic G, Romas E, Clemens L, Wilson AM, Nikpour M, Prior DL, Best JD, Jenkins AJ: Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Intern Med J 2006, 36(4):237-243.
22. Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, Prior D, Romas E, Clemens L, Dragicevic G, Harianto H, Wicks I, McColl G, Best J, Jenkins A: Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003, 48(1):81-89.
23. Jenkins AJ, Zhang SX, Rowley KG, Karschimkus CS, Nelson CL, Chung JS, O’Neal DN, Januszewski AS, Croft KD, Mori TA, Dragicevic G, Harper CA, Best JD, Lyons TJ, Ma JX: Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in Type 1 diabetes. Diabet Med 2007, 24(12):1345-1351.
24. Johnson CA, Levey AS, Coresh J, Levin A, Lau J, Eknoyan G: Clinical practice guidelines for chronic kidney disease in adults: Part II. Glomerular filtration rate, proteinuria, and other markers. Am Fam Physician 2004, 70:1091-1097.
25. Chao J, Chao L: Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe Seyler 1995, 376(12):705-713.
26. Thongboonkerd V, Malasit P: Renal and urinary proteomics: current applications and challenges. Proteomics 2005, 5(4):1033-1042.
27. Chen LM, Song Q, Chao L, Chao J: Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. Kidney Int 1995, 48(3):690-697.
28. Chao J, Bledsoe G, Yin H, Chao L: The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem 2006, 387(6):665-675.
29. Tessari P, Kiwanuka E, Barazzoni R, Vettore M, Zanetti M: Diabetic nephropathy is associated with increased albumin and fibrinogen production in patients with type 2 diabetes. Diabetologia 2006, 49(8):1955-1961.
30. Chen L-M, Ma J-X, Liang Y-M, Chao L, Chao J: Tissue kallikrein-binding protein reduces blood pressure in transgenic mice. J Biol Chem 1996, 271:27590-27594.
31. Chen L-M, Chao L, Chao J: Adenoviral-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. Hum Gene Ther 1997, 8:341-347.
32. Chen L-M, Chao L, Chao J: Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci 1996, 60:1431-1436.
33. Jenkins AJ, Rothen M, Klein RL, Moller K, Eldridge L, Zheng D, Durazo- Arvizu R, McGee D, Lackland D, Thorpe SR, Garvey WT, Lyons TJ, DCCT/EDIC Research Group: Cross-sectional associations of C-reactive protein with
vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications 2008, 22(3):153-163.
34. Lopes-Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins AJ, Lyons TJ, Garvey WT, Virella G, Diabetes Control and Complications Trial/ Epidemiology of Diabetes Intervention and Complications Cohort Study Group: Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 2008, 31(10):2006-2012.
35. Wang CR, Chen SY, Shiau AL, Wu CL, Jou IM, Chao L, Chao J: Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol 2007, 34(11):2171-2176.
36. Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, Chao L, Chao J: Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 2005, 52:1319-1324.
37. Bläckberg M, Berling R, Ohlsson K: Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose ntraperitoneal aprotinin. Pancreas 1999, 19(4):325-334.
38. Chao J, Chen LM, Chai KX, Chao L: Expression of kallikrein-bonding protein and _1-antitrypsin genes in response to sex hormones, growth, inflammation and hypertension. Agents Actions Suppl 1992, 174-181.
39. Chen LM, Chao L, Chao J: Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci 1997, 60:1431-1435.